249 related articles for article (PubMed ID: 22912851)
1. Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease.
Cabrera-Salazar MA; Deriso M; Bercury SD; Li L; Lydon JT; Weber W; Pande N; Cromwell MA; Copeland D; Leonard J; Cheng SH; Scheule RK
PLoS One; 2012; 7(8):e43310. PubMed ID: 22912851
[TBL] [Abstract][Full Text] [Related]
2. CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.
Marshall J; Sun Y; Bangari DS; Budman E; Park H; Nietupski JB; Allaire A; Cromwell MA; Wang B; Grabowski GA; Leonard JP; Cheng SH
Mol Ther; 2016 Jun; 24(6):1019-1029. PubMed ID: 26948439
[TBL] [Abstract][Full Text] [Related]
3. Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease.
Blumenreich S; Yaacobi C; Vardi A; Barav OB; Vitner EB; Park H; Wang B; Cheng SH; Sardi SP; Futerman AH
J Neurochem; 2021 Mar; 156(5):692-701. PubMed ID: 32743826
[TBL] [Abstract][Full Text] [Related]
4. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.
Farfel-Becker T; Vitner EB; Kelly SL; Bame JR; Duan J; Shinder V; Merrill AH; Dobrenis K; Futerman AH
Hum Mol Genet; 2014 Feb; 23(4):843-54. PubMed ID: 24064337
[TBL] [Abstract][Full Text] [Related]
5. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.
Sun Y; Liou B; Ran H; Skelton MR; Williams MT; Vorhees CV; Kitatani K; Hannun YA; Witte DP; Xu YH; Grabowski GA
Hum Mol Genet; 2010 Mar; 19(6):1088-97. PubMed ID: 20047948
[TBL] [Abstract][Full Text] [Related]
6. Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease.
Cabrera-Salazar MA; Bercury SD; Ziegler RJ; Marshall J; Hodges BL; Chuang WL; Pacheco J; Li L; Cheng SH; Scheule RK
Exp Neurol; 2010 Oct; 225(2):436-44. PubMed ID: 20673762
[TBL] [Abstract][Full Text] [Related]
7. Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1.
Srikanth MP; Jones JW; Kane M; Awad O; Park TS; Zambidis ET; Feldman RA
Stem Cells Transl Med; 2021 Jul; 10(7):1081-1094. PubMed ID: 33656802
[TBL] [Abstract][Full Text] [Related]
8. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.
McEachern KA; Fung J; Komarnitsky S; Siegel CS; Chuang WL; Hutto E; Shayman JA; Grabowski GA; Aerts JM; Cheng SH; Copeland DP; Marshall J
Mol Genet Metab; 2007 Jul; 91(3):259-67. PubMed ID: 17509920
[TBL] [Abstract][Full Text] [Related]
9. Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model.
Dasgupta N; Xu YH; Li R; Peng Y; Pandey MK; Tinch SL; Liou B; Inskeep V; Zhang W; Setchell KD; Keddache M; Grabowski GA; Sun Y
Hum Mol Genet; 2015 Dec; 24(24):7031-48. PubMed ID: 26420838
[TBL] [Abstract][Full Text] [Related]
10. A new brain-penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease.
Fujii T; Tanaka Y; Oki H; Sato S; Shibata S; Maru T; Tanaka Y; Tanaka M; Onishi T
J Neurochem; 2021 Nov; 159(3):543-553. PubMed ID: 34398463
[TBL] [Abstract][Full Text] [Related]
11. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
Bennett LL; Turcotte K
Drug Des Devel Ther; 2015; 9():4639-47. PubMed ID: 26345314
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
Barnes S; Xu YH; Zhang W; Liou B; Setchell KD; Bao L; Grabowski GA; Sun Y
PLoS One; 2014; 9(12):e116023. PubMed ID: 25551612
[TBL] [Abstract][Full Text] [Related]
13. Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy.
Boddupalli CS; Nair S; Belinsky G; Gans J; Teeple E; Nguyen TH; Mehta S; Guo L; Kramer ML; Ruan J; Wang H; Davison M; Kumar D; Vidyadhara DJ; Zhang B; Klinger K; Mistry PK
Elife; 2022 Aug; 11():. PubMed ID: 35972072
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease.
Nilsson O; Svennerholm L
J Neurochem; 1982 Sep; 39(3):709-18. PubMed ID: 7097276
[TBL] [Abstract][Full Text] [Related]
15. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
Marshall J; McEachern KA; Chuang WL; Hutto E; Siegel CS; Shayman JA; Grabowski GA; Scheule RK; Copeland DP; Cheng SH
J Inherit Metab Dis; 2010 Jun; 33(3):281-9. PubMed ID: 20336375
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of Glucosylceramide Synthase.
Shayman JA; Hinkovska-Galcheva V; Shu L
Methods Mol Biol; 2023; 2613():271-288. PubMed ID: 36587085
[TBL] [Abstract][Full Text] [Related]
17. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.
Schiffmann R; Cox TM; Dedieu JF; Gaemers SJM; Hennermann JB; Ida H; Mengel E; Minini P; Mistry P; Musholt PB; Scott D; Sharma J; Peterschmitt MJ
Brain; 2023 Feb; 146(2):461-474. PubMed ID: 36256599
[TBL] [Abstract][Full Text] [Related]
18. Gaucher Disease: A Glance from a Medicinal Chemistry Perspective.
Prencipe F; Barzan C; Savian C; Spalluto G; Carosati E; De Amici M; Mosconi G; Gianferrara T; Federico S; Da Ros T
ChemMedChem; 2024 May; 19(10):e202300641. PubMed ID: 38329692
[TBL] [Abstract][Full Text] [Related]
19. Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease.
Hamler R; Brignol N; Clark SW; Morrison S; Dungan LB; Chang HH; Khanna R; Frascella M; Valenzano KJ; Benjamin ER; Boyd RE
Anal Chem; 2017 Aug; 89(16):8288-8295. PubMed ID: 28686011
[TBL] [Abstract][Full Text] [Related]
20. Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants.
Nilsson O; Grabowski GA; Ludman MD; Desnick RJ; Svennerholm L
Clin Genet; 1985 May; 27(5):443-50. PubMed ID: 3924448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
